

Pain Management Tele-mentoring for Remote Providers: Project ECHO

*Joanna G Katzman, MD, MSPH
Director University of New Mexico Pain Center and
Project ECHO Pain*

Conflict of Interest- Nothing to Disclose

Project ECHO® (Extension for Community Health Care Outcomes)

The mission of Project ECHO® is to expand the capacity to provide best practice care for common and complex diseases in rural and underserved areas and to monitor outcomes.

Supported by N.M. Dept. of Health, Agency for Health Research and Quality HIT Grant 1 UC1 HS015135-04, New Mexico Legislature, and the Robert Wood Johnson Foundation.

Hepatitis C: A Global Health Problem

Over 170 Million Carriers Worldwide, 3-4 MM new cases/year



Source: WHO 1999

OBJECTIVES: At the end of the presentation you should be able to:

1. Differentiate TeleECHO™ from traditional telemedicine.
2. Describe the impact of the ECHO Model™ on clinician knowledge, skills and practice.
3. Describe how the Hub/Spoke design builds interprofessional teams who can improve patient care for those with common and complex diseases, including pain and addictions.
4. Consider the need to develop an ECHO Pain and Addictions program in your region as a means to meet the public health challenges identified in the DoD and IOM reports.

HEALTHCARE DILEMMA

- How can a specialist better manage thousands of patients who live hundreds of miles from his office?
- How can specialty care reach underserved minorities?
- How can this be accomplished without adding to the workforce?
- How can this be accomplished with existing infrastructure?

Hepatitis C in New Mexico

- Estimated number is greater than 28,000
- In 2004 less than 5% had been treated
 - 2,300 prisoners were HCV positive (~40% of those entering the corrections system), none were treated
- Highest rate of chronic liver disease/cirrhosis deaths in the nation; 25% higher incidence than the next highest state
- Ten times more prevalent than HIV

Hepatitis C Treatment

- Good News
- Curable in 45-81% of cases
- Bad News
- Severe side effects:
 - anemia (100%)
 - neutropenia >35%
 - depression >25%
- No Primary Care Physicians treating HCV

Goals of Project ECHO®

- **Develop capacity to safely and effectively treat HCV in all areas of New Mexico and to monitor outcomes**
- **Develop a model to treat complex diseases in rural locations and developing countries**

Methods

- **Use Technology (multipoint videoconferencing and Internet) to leverage scarce healthcare resources**
- **Disease Management Model focused on improving outcomes by reducing variation in processes of care and sharing “best practices”**
- **Case based learning: Co-management of patients with UNMHSC specialists (learning by doing)**
- **HIPAA compliant web-based database to monitor outcomes**


Arora S, Geppert CM, Kalishman S, et al: Acad Med. 2007 Feb;82(2): 154-60.

Steps

- Train physicians, mid-level providers, nurses, pharmacists, educators in HCV
- Train to use web based software — “iHealth”
- Conduct telemedicine clinics — “Knowledge Network”
- Initiate co-management — “Learning Loops”
- Collect data and monitor outcomes centrally
- Assess cost and effectiveness of programs

Benefits to Rural Clinicians

- **No cost CMEs and Nursing CEUs**
- **Professional interaction with colleagues with similar interest**
 - **Less isolation with improved recruitment and retention**
- **A mix of work and learning**
- **Obtain HCV certification**
- **Access to specialty consultation with GI, hepatology, psychiatry, infectious diseases, addiction specialist, pharmacist, patient educator**



ECHO Whale



PCA Espanola



Baton Rouge



Pecos Valley MC



DOH Las Cruces



SBRT-First Choice South Vc



Memorial HDX7000



LAS VEGAS ECFH

NEJM : 364: 23, June 9-2011, Arora S, Thornton K, Murata G



Clustering of Poor Prognostic Factors in Heavy Patients


Weight, kg (lb)	< 75.0 (1,650)	≥ 75.0 (1,651)*
Male, n (%)	500 (66.5)	1075 (66.5)**
Black Race, n(%)	171 (22.5)	36 (2.2)*
Age, years†	63.5 ± 16.4	63.5 ± 16.4†
BMV, kg/m ³ †	32.2 ± 8.7	32.2 ± 8.7†
Diastolic, n (%)	101 (13.2)	103 (6.4)**
Log HbA1c (mmol/L)†	9.30 ± 1.77	9.40 ± 1.62†
HbA1c, n (%)	702 (91.5)	600 (36.5)**
Smoking, n (%)	342 (45.0)	300 (18.5)**
Residence in US	201 (26.5)	311 (19.2)**

Clustering of Poor Prognostic Factors in Heavy Patients

Weight, kg (lb)	< 75.0 (1,651)*
Male, n (%)	500 (66.5)
Black Race, n(%)	171 (22.5)
Age, years†	63.5 ± 16.4
BMV, kg/m ³ †	32.2 ± 8.7
Diastolic, n (%)	101 (13.2)
Log HbA1c (mmol/L)†	9.30 ± 1.77
HbA1c, n (%)	702 (91.5)
Smoking, n (%)	342 (45.0)
Residence in US	201 (26.5)

DRUG INFORMATION HANDBOOK

TeleECHO[®] Clinic Architecture



How well has model worked for Hepatitis C?

- 500 HCV TeleECHO Clinics have been conducted
- >5,000 patients entered HCV disease management program

CME's/CE's issued:

- 6000 hours of CME for HCV
- Total CME hours 27,000 at no cost in 13 different areas

Project ECHO[®] Clinicians

HCV Knowledge Skills and Abilities (Self-Efficacy)

scale: 1 = none or no skill at all 7= expert-can teach others

Community Clinicians N=25	<u>BEFORE</u> Participation MEAN (SD)	<u>TODAY</u> MEAN (SD)	Paired Difference (p-value) MEAN (SD)	<u>Effect</u> <u>Size</u> for the change
1. Ability to identify suitable candidates for treatment for HCV.	2.8 (1.2)	5.6 (0.8)	2.8 (1.2) (<0.0001)	2.4
2. Ability to assess severity of liver disease in patients with HCV.	3.2 (1.2)	5.5 (0.9)	2.3 (1.1) (< 0.0001)	2.1
3. Ability to treat HCV patients and manage side effects.	2.0 (1.1)	5.2 (0.8)	3.2 (1.2) (<0.0001)	2.6

Project ECHO[®] Clinicians

HCV Knowledge Skills and Abilities (Self-Efficacy)

Community Clinicians N=25	<u>BEFORE</u> Participation MEAN (SD)	<u>TODAY</u> MEAN (SD)	Paired Difference (p-value) MEAN (SD)	<u>Effect</u> <u>Size</u> for the chang e
4. Ability to assess and manage psychiatric co-morbidities in patients with hepatitis C.	2.6 (1.2)	5.1 (1.0)	2.4 (1.3) (<0.0001)	1.9
5. Serve as local consultant within my clinic and in my area for HCV questions and issues.	2.4 (1.2)	5.6 (0.9)	3.3 (1.2) (< 0.0001)	2.8
6. Ability to educate and motivate HCV patients.	3.0 (1.1)	5.7 (0.6)	2.7 (1.1) (<0.0001)	2.4

Project ECHO[®] Clinicians

HCV Knowledge Skills and Abilities (Self-Efficacy)

Community Clinicians N=25	<u>BEFORE</u> Participation MEAN (SD)	<u>TODAY</u> MEAN (SD)	Paired Difference (p-value) MEAN (SD)	<u>Effect</u> <u>Size</u> for the change
Overall Competence (average of 9 items)	2.8* (0.9)	5.5* (0.6)	2.7 (0.9) (<0.0001)	2.9

Cronbach's alpha for the BEFORE ratings = 0.92 and Cronbach's alpha for the TODAY ratings = 0.86 indicating a high degree of consistency in the ratings on the 9 items

Arora S, Kalishman S, Thornton K, Dion D et al: Hepatology. 2010 Sept;52(3):1124-33

Clinician Benefits

(Data Source; 6 month Q-5/2008)

Benefits N=35	Not/Minor Benefits	Moderate/Major Benefits
Enhanced knowledge about management and treatment of HCV patients.	3% (1)	97% (34)
Being well-informed about symptoms of HCV patients in treatment.	6% (2)	94% (33)
Achieving competence in caring for HCV patients.	3% (1)	98% (34)

Project ECHO[®]

Annual Meeting Survey

N=17	Mean Score (Range 1-5)
Project ECHO [®] has diminished my professional isolation.	4.3
My participation in Project ECHO [®] has enhanced my professional satisfaction.	4.8
Collaboration among agencies in Project ECHO [®] is a benefit to my clinic.	4.9
Project ECHO [®] has expanded access to HCV treatment for patients in our community.	4.9
Access, <u>in general</u> , to specialist expertise and consultation is a major area of need for you and your clinic.	4.9
Access to <u>HCV specialist</u> expertise and consultation is a major area of need for you and your clinic.	4.9

The Hepatitis C Trial

OBJECTIVES

- To train primary care clinicians in rural areas and prisons to deliver Hepatitis C treatment to rural populations of New Mexico
- To show that such care is as safe and effective as that given in a university clinic
- To show that Project ECHO[®] improves access to Hepatitis C care for minorities

Participants

- Study sites
 - Intervention (ECHO)
 - Community-based clinics: 16
 - New Mexico Department of Corrections: 5
 - Control: University of New Mexico (UNM) Liver Clinic
- Subjects meeting inclusion / exclusion criteria
 - Community cases seen by primary care physicians
 - Consecutive University patients

PRINCIPAL ENDPOINT

- Sustained Viral Response (SVR): no detectable virus 6 months after completion of treatment

TREATMENT OUTCOMES

Outcome	ECHO [®]	UNMH	P-value
	N=261	N=146	
Minority	68%	49%	P<0.01
SVR* (Cure) Genotype 1	50%	46%	NS
SVR* (Cure) Genotype 2/3	70%	71%	NS

*SVR=sustained viral response

NEJM : 364: 23, June 9-2011, Arora S, Thornton K, Murata G

Conclusions


- Rural primary care Clinicians deliver hepatitis C care under the aegis of Project ECHO[®] that is as safe and effective as that given in a University clinic.
- Project ECHO[®] improves access to hepatitis C care for New Mexico minorities.

Disease Selection

- Common diseases
- Management is complex
- Evolving treatments and medicines
- High societal impact (health and economic)
- Serious outcomes of untreated disease
- Improved outcomes with disease management


Force Multiplier

Use Existing Community Clinicians




Successful Expansion into Multiple Diseases

Monday	Tuesday	Wednesday	Thursday	Friday
<p>Rheumatology</p> <ul style="list-style-type: none"> A Bankhurst, MD <p>Complex Care</p> <ul style="list-style-type: none"> D Neale, MD J Katzman, MD M Komaromy, MD 	<p>Women's Health & Genomics</p> <ul style="list-style-type: none"> LB Curet, MD <p>Dementia</p> <ul style="list-style-type: none"> J Knoefel, MD J Kelly, MD C Herman, MD <p>HIV/AIDS</p> <ul style="list-style-type: none"> M Iandiorio, MD E Thomas, MD <p>Diabetes – CHW CREW</p> <ul style="list-style-type: none"> K Colleran, MD 	<p>Diabetes & Cardiovascular</p> <ul style="list-style-type: none"> K Colleran, MD B Cox, MD <p>Palliative Care</p> <ul style="list-style-type: none"> D Neale, MD L Marr, MD <p>Hepatitis C: Community</p> <ul style="list-style-type: none"> S Arora, MD K Thornton, MD 	<p>Chronic Pain</p> <ul style="list-style-type: none"> J Katzman, MD G Comerci, MD <p>Prison Peer Education Program</p> <ul style="list-style-type: none"> K Thornton, MD 	<p>Integrated Addiction/Psychiatry</p> <ul style="list-style-type: none"> M Komaromy, MD L Hayes, MD



TRANSFORMING PRIMARY CARE WITH KNOWLEDGE NETWORKS



“Expanding the Definition of Underserved Population”

Potential Benefits of ECHO[®] model to Health System

- Quality and Safety
- Rapid Learning and best-practice dissemination
- Reduce variations in care
- Access for Rural and Underserved Patients, reduced disparities
- Workforce Training and Force Multiplier
- De-monopolize Knowledge
- Improving Professional Satisfaction/Retention
- Supporting the Medical Home Model
- Cost Effective Care- Avoid Excessive Testing and Travel
- Prevent Cost of Untreated Disease (e.g.: liver transplant or dialysis)
- Integration of Public Health into treatment paradigm

ECHO[®] Replication:


- University of Washington (HCV, Chronic Pain, HIV, Addiction)
- University of Chicago (HTN, Cancer, ADHD)
- Veteran's Administration Health System (Chronic Pain, DM, Heart Failure, HCV, Women's Health, Nephrology)
- Department of Defense, Army (Pain)
- University of Nevada (DM)
- University of Utah (HIV/AIDS)
- University of South Florida, ETAC (HCV/HIV Co-Infection)
- Florida and Caribbean, AETC (HIV/AIDS)
- Harvard, Beth Israel Deaconess Medical Center (HCV, Dementia)
- Community Health Center, Inc. (HIV, HCV, Chronic Pain)
- India, New Delhi (HIV, HCV)
- India, Lucknow (Autism)
- Uruguay (Liver Disease)
- Indian Health Service (Pain/Addiction)

TWO PUBLIC HEALTH CRISES

Chronic Pain Management


Substance Abuse and Addictions

Substance Abuse Treatment Admissions: Rx Opioids, 2007



Only 8 states had a lower rate of treatment admissions for prescription opioids

Drug Overdose Death Rates, 2008 (per 100,000 population)



New Mexico had the highest rate of drug overdose deaths (all drugs)


Integrated Addictions and Psychiatry Clinic

- Focus on treating opioid addiction (heroin, prescription opioid analgesics) with psychosocial support + effective medication
- Only 32 physicians in New Mexico certified to prescribe Buprenorphine in 2007
- Trained/certified 225 physicians statewide in use of buprenorphine/Suboxone, 274 total clinicians trained



Certified Buprenorphine Providers (rural, low income, hispanic)

Currently there are 632 Zip Codes in the US with the following characteristics:
 1) Rural (less than 1,000 people per sq mile.)
 2) 40% or more people identify themselves as Hispanic.
 3) The average household income is less than \$44,100.

5,373,209 people reside in these zip codes, with 756,578 of those living in NM. There are 145 licensed providers residing within these zip codes, 72 within New Mexico. This graph shows when each provider became licensed.



Core Pain Publications



BACKGROUND: Need for a Pain ECHO

- Unintentional Drug Overdose Death Rates in New Mexico reaching a Public Health Crisis
- Opiates frequently involved in the overdose death (but not the only drug)
- Death Rates predominantly seen in adolescents and young adults
- Unintentional Opiate-related Death rates in New Mexico now EXCEED motor vehicle accident deaths

2009: UNM ECHO Pain Program

- To address scarce pain management expertise in New Mexico
 - Over 6 month wait times for pain consultation at UNM Pain Center
 - Improve Primary Care clinical knowledge, skills and confidence managing chronic pain
 - Safe Opioid prescribing
 - Behavioral Health and Addiction Risk
 - Interdisciplinary Multimodal Therapies (best practices)

Goals for Chronic Pain ECHO®


- Education of primary care providers and other allied health professionals
 - Curriculum – didactics and demonstrations that build upon each other
 - Case-based learning
 - Workplace learning
 - Mini-residency, 2-Day training

Goals for Chronic Pain ECHO®

- Best practices for safe and effective treatment
- Utilize technology to co-manage patients at remote sites
- Evaluate program; Research patient population outcomes



Concept of “Force Multiplication” via Hub/Spoke Design



ECHO ID: 13160
Gender: Female

Age: 40
Presenter: Boyle, Jeannie

Presented: 02/14/2013 Initial

Presenter: Boyle, Jeannie

MAIN QUESTION FOR PRESENTATION

POOR PAIN CONTROL, seek general advice on what to do

PAIN CONDITION

Female Pelvic Pain; Fibromyalgia; Pain in Joint; Complex Regional Pain Syndrome, Unspecified; Other: Body dysmorphic somatiform disorder; L. knee ACL tear; L. Ankle Ligament tear w/diagn changes

ABERRANT OPIOID USE SCREENING SCORES

DEMOGRAPHICS AND SOCIAL HISTORY

Race, Ethnicity & Scheduling
Employment & Social Situation
Unemployed; Married

PAIN HISTORY

Description of pain problem: Wheelchair bound woman- with Left knee ACL tear Left an...

Average pain severity: 9
What exacerbates: Left LE painful to touch

MEDICATIONS

Polyethylene Glycol 3350- 17 - Daily,
Eszopiclone- 1 - QHS,
Escitalopram- 5 - Daily,
Esomeprazole- 40 - BID,
Methocarbamol- 500 - TID,
Morphine (MS Contin)- 30 - BID,
Morphine (MS Contin)- 15 - BID,
Duloxetine- 90 - Daily,
Cyanocobalamin- 1000 - Q Week,
Pregabalin- 150 - QID,
Polyethylene Glycol 3350 - Other,
Buprenorphine patch- 10 - Q Week,

TREATMENT HISTORY

Medications
NSAIDs [unknown if helpful]; Long Acting [unknown if helpful]; Short Acting [not helpful]; Baclofen [not helpful]; Tramidine [unknown if helpful]; Other: Fentanyl patch, Codeine and Percocet, Dilaudid, Lortab, Vicodin, Tramadol

Injections & Interventions
Ipadural Steroid Injection [unknown if helpful]; Facet Injection [unknown if helpful]; Spinal Cord Stimulator [not helpful]

Complimentary Alternative

Medicine
Physical Therapy/Exercise [unknown if helpful]

Psychosocial & Psychiatry
Other Treatments

SLEEP

Decreased

PSYCHIATRIC/SUBSTANCE USE HISTORY

PHQ2 Score
Psychiatric Diagnoses
Generalized Anxiety; Depression; Panic Attacks
Adverse Life Events History
Substance Use History
Nicotine: [no avg/day], [no last use date]
Morphine Equivalent Dose (MED)

NON-PAIN DIAGNOSES

CAD; Diabetes; Hypertension; Other: RA; OA; elevated liver enzymes

PHYSICAL EXAM

Vitals
Height-64.00in, Weight-170.00lb, BMI-29.18
Head
Tenderness in Muscle Groups
Extremities
Spine
Straight Leg Raise
Left Straight Leg Raise [abnormal]; Right Straight Leg Raise [abnormal]
Other Physical Exam Findings
Constipation, Fatigue, In wheelchair

PAIN IMAGE



PERTINENT IMAGING & MONITORING

Pertinent Imaging Studies
Drug Monitoring

Current Labs

Last Note:

[Empty text box for last note]

Clinic Note:

L LE CRPS--but this dx is questioned due to lack of clarifying information (other

Addendum:

[Empty text box for addendum]

Back to Patient Clinic

Previous Presentations:

02/14/2013 Initial

Sign Off Person:

Shelley, Brian

Edit All Save Cancel Print

'iHealth' Pain Management Tool



Pain Curricula Split into 5 Week Modules

- Module 1 Chronic Pain Essentials
- Module 2 Opioids and Addictions
- Module 3 Psychology of Chronic Pain
- Special Topics Modules
 - Integrative Series
 - Complex Regional Pain Syndrome
 - Other Pain Syndromes

MODULE 2 satisfies NM opiate pain management mandates

TITLE 16 OCCUPATIONAL AND PROFESSIONAL LICENSING
CHAPTER 10 MEDICINE AND SURGERY PRACTITIONERS
PART 14 MANAGEMENT OF PAIN WITH CONTROLLED SUBSTANCES

16.10.14.1 **ISSUING AGENCY:** New Mexico Medical Board, hereafter called the board.
[16.10.14.1 NMAC - N, 1/20/03; A, 4/3/05]

16.10.14.2 **SCOPE:** This part applies to all New Mexico medical board licensees who hold a federal drug enforcement administration registration.
[16.10.14.2 NMAC - N, 1/20/03; A, 9/28/12]

16.10.14.3 **STATUTORY AUTHORITY:** These rules are promulgated pursuant to and in accordance with the Medical Practice Act, Sections 61-6-1 through 61-6-35 NMSA 1978 and the Pain Relief Act, Sections 24-2D-1 through 24-2D-6.
[16.10.14.3 NMAC - N, 1/20/03; A, 9/28/12]

16.10.14.4 **DURATION:** Permanent
[16.10.14.4 NMAC - N, 1/20/03]

16.10.14.5 **EFFECTIVE DATE:** January 20, 2003, unless a later date is cited at the end of a section.
[16.10.14.5 NMAC - N, 1/20/03]

16.10.14.6 **OBJECTIVE:** It is the position of the board that practitioners have an obligation to treat chronic pain and that a wide variety of medicines including controlled substances and other drugs may be prescribed for that purpose. When such medicines and drugs are used, they should be prescribed in adequate doses and for appropriate lengths of time after a thorough medical evaluation has been completed.
[16.10.14.6 NMAC - N, 1/20/03; A, 4/3/05]

16.10.14.7 **DEFINITIONS:**
A. "Addiction" is a neurobehavioral syndrome with genetic and environmental influences that results

MODULE 2: Opioids and Addictions

OPIOID INDICATIONS AND USE

CHRONIC OPIOID TREATMENT: MEDICAL CONCERNS

CHRONIC OPIOID TREATMENT: BEHAVIORAL CONCERNS

ADDICTIONS AND CHRONIC PAIN

NON-OPIOID CHRONIC PAIN MEDICATIONS


ECHO Pain Replication in North America



ECHO replication in North America

- University of Washington (Tele-Pain)*
- Veteran's Administration (SCAN ECHO)*
- Community Health Centers (CT, AZ, CA)*
- Department of Defense (Army Pain ECHO)*
- Canada Pain and Addictions - in progress (Ontario)*
- I H S National Center for TeleBehavioral Health (ECHO Pain and Addiction)*

ARMY PAIN ECHO PHASED ROLL OUT



Slide courtesy of OTSG staff


Deliberate Army Phased Roll Out

- PREPARATORY PHASE
 - IT support
 - VTC readiness
 - Adequate staffing
- OBSERVATION PHASE
 - 2 day Bootcamp
 - Mock Clinics
 - Hands-on Skills
- INITIAL 2 MONTH MENTORING
 - Army joins ECHO
 - Participates in curriculum and demonstrations
 - Builds relationships across Army
 - Cases presented weekly
- HUB ROLL OUT PHASE
 - 2 months' distance mentoring by UNM ECHO faculty

UNCLASSIFIED // FOUO




Growth of ECHO Pain Tele-mentoring Clinic




**Unique attendees and sites joining Pain TeleECHO Clinics
2009-2012**

Interdisciplinary Breakdown (attendees)



Anonymous CME Evaluation Results for ECHO Pain – Change in proportion of excellence ratings demonstrated graphically by question and year and tested using a Chi-Square Goodness of Fit test for the period from 2010 through 2012.

Change in Proportion of Excellence Ratings by Question and Year for ECHO Pain



CME Rating Measure	N	DF	X ² Statistic	Cramer's V [†]	P-Value	Relative Change [‡] , 2010 vs. 2012
Effective?	755	2	13.14	0.13	0.0014	24%
Balanced?	752	2	16.76	0.15	0.0002	26%
Met Objectives?	758	2	27.58	0.19	<0.0001	37%
Opportunities to ask questions?	696	2	17.16	0.16	0.0002	35%
Relevance?	590	2	11.70	0.14	0.0029	27%

† A scale for interpreting the Cramer's V effect size is: 0.10 = small; 0.30 = medium; 0.50 = large.

‡ Relative change is the proportional increase in percentage of respondents rating "Excellent"

Continuing medical education 2012 UNM ECHO Pain Program

1,863 hours of educational credits for
professional licensure:*

*MD, DO, NP, PA, RN, SW, PT, DDS, PharmD***

**Over 4,500 CME issued since 2009*

***Evaluations rate our program “Excellent” and
“Relevant to my practice” ($p < .05$)*

Treating Chronic Pain in New Mexico: Addressing Best Practices, Addiction, and Current Regulations

*This course is approved by the
NM Medical Board to fulfill the
5 hour requirement related to
Management of Chronic Pain
with Controlled Substances.*

N >1,500
Trained by
ECHO Pain
faculty to
date

Presented by:



SCHOOL of MEDICINE
UNM Pain Consultation & Treatment Center
Department of Neurosurgery



Albuquerque • Santa Fe • Las Cruces
New Mexico
Saturdays, 8:00 am - 1:30 pm


November 3, 2012	Domenici Auditorium, UNM North Campus, Albuquerque
December 8, 2012	Domenici Auditorium, UNM North Campus, Albuquerque
January 26, 2013	La Fonda Hotel, Santa Fe, New Mexico
February 23, 2013	VA Health Care System, Albuquerque
April 6, 2013	Hotel Encanto, Las Cruces, New Mexico
May 18, 2013	Domenici Auditorium, UNM North Campus, Albuquerque

Special Opiate Education-


**Required for licensure in NM*

- Comprised of one 5 hour training
 - Saturday; various locations in NM
- 1,100 Providers Trained in 6 training days
- 1,075 consented/matched sets analyzed
- ***Statistically Significant increases resulted:***
 - ***Knowledge of Opiates***
 - ***Self Efficacy Managing Opiates***
 - ***Perceived Value to Practice***

Degree



Specialty



Knowledge

Measure	Pre Mean	Post Mean	Difference					
			n	Mean	SD	Student's t	P-value	Effect Size(d) [†]
Test Score (10 Possible)	7.04	8.77	1075	1.73	1.71	23.42	<0.0001	1.01
Percent Score (100% possible)	70.4%	87.7%	1075	17.3%	17.1%	23.42	<0.0001	1.01

Self-Efficacy

Overall Rating: Tests for Significance

Measure	Pre Mean	Post Mean	Difference					Effect Size(d) [†]
			n	Mean	SD	Student's t	P-value	
Overall Rating (7 Possible)	4.53	5.45	1075	0.92	0.88	24.14	<0.0001	1.04
Percent Rating (100% possible)	64.7%	77.8%	1075	13.1%	12.6%	24.14	<0.0001	1.04

ECHO Awards/Honors of Distinction

- 2009 Robert Wood Johnson Foundation
- 2011 American Pain Society Clinical Center of Excellence
- 2012 National Institutes of Health Centers of Excellence in Pain Education



NIH Pain Consortium
Centers of Excellence in Pain Education



Conclusions

1. The ECHO Model™ fills a community need, and differs from individual patient care (addressed in traditional telemedicine).
2. The ECHO Pain model offers a successful, practical and cost effective solution to recommendations made in the DoD and IOM reports on pain.
3. Improved knowledge, skills and practice change are demonstrated in an Interprofessional Collaborative Practice.
4. Successful replications of ECHO Pain (and ECHO Pain/Addictions) across the country demonstrate the need for this approach.
5. Lifelong learning through a tele-mentoring social network enhances practice and improves outcomes.

Project ECHO[®]

... promotes care in underserved areas

The mission of Project ECHO[®] (Extension for Community Healthcare Outcomes) has been to develop the capacity to safely and effectively treat chronic, common, and complex diseases in rural and underserved areas, and to monitor outcomes of this treatment.

Project ECHO[®] is funded in part by a grant from the Robert Wood Johnson Foundation and has received support from the New Mexico Legislature, the University of New Mexico, the New Mexico Department of Public Health and Agency for Healthcare Research and Quality.